Inotrem announces publication of two key articles on nangibotide Phase II programs in peer-reviewed medical journals
June 1, 2023
Paris (France). June 1st. 2023. Inotrem, an advanced clinical stage biotech company specializing in immunotherapies for acute and chronic inflammatory conditions, announced today the publication